Pain management最新文献

{"title":"The role of liposomal bupivacaine in pain management after the NOPAIN act.","authors":"Yash Shah, Anthony Barisano, Eric Ly, Vendhan Ramanujam","doi":"10.1080/17581869.2025.2525740","DOIUrl":"10.1080/17581869.2025.2525740","url":null,"abstract":"","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"449-451"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144507522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative cryoneurolysis for peri- and postoperative pain in total knee arthroplasty: a systematic review and pooled analysis.","authors":"Brandon Goodwin, Hanna Brancaccio, Mitchell Kaplan, Valerie Rome, Sameer Shah, Sweta Mukhopadhyay, Seungkyu Park, Gilbert Siu","doi":"10.1080/17581869.2025.2522063","DOIUrl":"10.1080/17581869.2025.2522063","url":null,"abstract":"<p><strong>Background: </strong>Cryoneurolysis is seeing increased implementation in total knee arthroplasty (TKA), providing postoperative analgesia through preoperative cryoneurolysis of peripheral nerves. Thus, we are conducting this systematic review and meta-analysis to determine cryoneurolysis' efficacy in providing analgesia and improvements in recovery times for patients undergoing TKA.</p><p><strong>Methods: </strong>We conducted a comprehensive search using five databases including PubMed, Cochrane Library, Web of Science, Embase, and Scopus. The screened articles were assessed for inclusion of primary outcomes: pain scores before nerve cryoablation, peri- and post-operative pain scores in TKA, length of pain relief, patient demographics, and type of pain score employed. The Higgins I² test served to discern the degree of heterogeneity between included studies. Cohen's d was utilized to interpret the pooled effect size of the studies.</p><p><strong>Results: </strong>Our search yielded six articles that met our inclusion criteria. The overall effect size illustrated a d = 1.468 (95% CI: 1.084-1.851; <i>p</i> < 0.001) for the Visual Analog Score (VAS), Numerical Rating Score (NRS), and Patient-Reported Outcomes Measurement Information System (PROMIS) pain subscore. Each individual study possessed a large effect size.</p><p><strong>Conclusion: </strong>Our comprehensive review and meta-analysis indicated that cryoneurolysis provides effective pain management, providing TKA patients with significant pain reduction for 6-12 weeks post-surgery. Furthermore, improvements were observed in patient-centered outcomes: mobility, return to routine activities, and overall satisfaction. Future studies should be conducted to determine the long-term efficacy of cryoneurolysis and the appropriate timing and duration of cryoneurolysis to maximize its analgesic abilities.</p><p><strong>Protocolregistration: </strong>www.crd.york.ac.uk/prospero identifier is CRD42024542005.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"527-534"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eptinezumab for migraine prevention after other treatments fail: a plain language summary of publications.","authors":"Messoud Ashina, Elena Ruiz de la Torre, Line Pickering Boserup, Anders Ettrup, Amaal J Starling","doi":"10.1080/17581869.2025.2514425","DOIUrl":"10.1080/17581869.2025.2514425","url":null,"abstract":"","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"453-466"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"STIMFIX™ anchoring in percutaneous spinal cord stimulation trials: interim analysis of a multicenter study.","authors":"Maja Green, Lakshmi Narra, Saurabh Dang, Jack Diep, Dipan Patel, Philip Lim, Joseph Atallah, Krishnan Chakravarthy","doi":"10.1080/17581869.2025.2527576","DOIUrl":"10.1080/17581869.2025.2527576","url":null,"abstract":"<p><strong>Aims: </strong>Lead migration during percutaneous spinal cord stimulation (SCS) trials can undermine therapeutic efficacy. This study evaluates the effectiveness of the novel, noninvasive STIMFIX anchoring system in reducing lead migration compared to conventional anchoring techniques.</p><p><strong>Patients & methods: </strong>This interim analysis included two prospectively collected cohorts. Group 1 (<i>n</i> = 28) was a randomized, single-center trial comparing three anchoring methods: sutures (<i>n</i> = 9), adhesive tape (<i>n</i> = 10), and manufacturer-provided anchors (<i>n</i> = 9). Group 2 (<i>n</i> = 20) was a multicenter, open-label, non-randomized study using STIMFIX anchors. Lead migration was measured via standardized fluoroscopic imaging on Days 1 and 7.</p><p><strong>Results: </strong>Mean lead migration in Group 1 was 33.5 mm (manufacturer anchor), 29.4 mm (tape), and 21.1 mm (sutures), with no significant differences between groups (<i>p</i> = 0.404). Group 2 demonstrated an average lead migration of 19.5 mm with STIMFIX. No major adverse events were reported; one case of minor skin irritation resolved without intervention.</p><p><strong>Conclusions: </strong>STIMFIX demonstrated reduced lead migration compared to conventional methods, with favorable safety and ease of application. These findings support its use as a promising advancement in SCS trial anchoring.</p><p><strong>Clinical trial registration: </strong>www.clinicaltrials.gov identifier is NCT05651646.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"477-489"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of diamagnetic therapy to manage a patient with degenerative cervical myelopathy and drug's intolerance.","authors":"Vincenzo Rania, Gianmarco Marcianò, Cristina Vocca, Caterina Palleria, Lucia Muraca, Pietro Romeo, Felipe Torres, Luca Gallelli","doi":"10.1080/17581869.2025.2523729","DOIUrl":"10.1080/17581869.2025.2523729","url":null,"abstract":"<p><p>Degenerative cervical myelopathy (DCM) is a common condition with a prevalence of 24.2% in the healthy population, and 35.3% in patients older than 60 years. The management of this clinical condition is difficult and implies chronic management of patients. The risk of drug abuse is very high and may lead to important long-term consequences. Finding a therapeutic option capable to reduce the number of prescribed drugs and with few side effects is very important in DCM. We report a 44-year-old Caucasian woman who was diagnosed with DCM. Her medical history revealed that despite using multiple medications, she did not show any signs of improvement. She declined the surgical treatment as well. Following clinical assessment, a diamagnetic pump treatment with pulsed electromagnetic fields for 3 months (once-twice weekly for 30 min, magnetic flux density 86 mt at the site of treatment) resulted in a clinical improvement. The benefits of diamagnetic therapy were three-faced including pain improvement, functional status, and imaging (magnetic resonance imaging (MRI) showing bone marrow edema reduction and myelopathy improvement). This is the first case report in our knowledge to prove the effectiveness of diamagnetic therapy in DCM, alongside imaging and functional improvement.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"373-378"},"PeriodicalIF":1.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposed versus disease-specific medicinals for the prophylaxis of migraine: an updated systematic review.","authors":"Savvas-Ilias Christofilos, Theodoros Mavridis, Viktor Gkotzamanis, Sofia Vasilopoulou, Christina I Deligianni, Dimos-Dimitrios Mitsikostas","doi":"10.1080/17581869.2025.2509474","DOIUrl":"10.1080/17581869.2025.2509474","url":null,"abstract":"<p><strong>Background: </strong>Gepants, selective antagonists of the calcitonin gene-related peptide (CGRP) receptor, and monoclonal antibodies targeting CGRP or its receptor (anti-CGRP mAbs) are promising migraine treatments, demonstrating superior tolerability than traditional preventives. While their efficacy over placebo is established, their comparative benefit-risk profiles remain to be fully elucidated.</p><p><strong>Objective: </strong>To indirectly compare the benefit-risk ratios of gepants with anti-CGRP mAbs and repurposed preventives.</p><p><strong>Methods: </strong>A comprehensive search of PubMed/MEDLINE and ClinicalTrials.gov was conducted to identify phase-3, placebo-controlled trials of gepants (atogepant, rimegepant), anti-CGRP mAbs (eptinezumab, erenumab, fremanezumab, galcanezumab), and traditional treatments (propranolol, topiramate, onabotulinumtoxinA). The number needed to treat (NNT) for achieving ≥50% reduction in migraine days and the number needed to harm (NNH) for adverse effects were calculated to determine the likelihood to help versus harm (LHH) values.</p><p><strong>Results: </strong>Twenty-seven studies were included: 15 of mAbs, 4 of gepants, 2 of onabotulinumtoxin A, and 6 of standard treatments. Atogepant and fremanezumab exhibited the highest LHH in episodic migraine, and galcanezumab and eptinezumab performed favorably in chronic migraine concerning treatment discontinuation and treatment-related adverse effects.</p><p><strong>Conclusions: </strong>Anti-CGRP/R medications present a more favorable benefit/risk ratio than traditional treatments. These findings, combined with individual patient histories and preferences, can inform clinical decision-making.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"425-439"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of intra-articular opioid injections for managing temporomandibular joint nociception: a systematic review.","authors":"Madhuli Bhide, P Emile Rossouw, Fawad Javed","doi":"10.1080/17581869.2025.2517523","DOIUrl":"10.1080/17581869.2025.2517523","url":null,"abstract":"<p><strong>Aim: </strong>This systematic review evaluated randomized controlled trials (RCTs) investigating the effectiveness of intra-articular opioid injections for managing temporomandibular joint (TMJ) pain.</p><p><strong>Methods: </strong>A comprehensive search of indexed databases and Google Scholar was conducted following PRISMA guidelines. Included studies assessed self-reported TMJ pain and maximum mouth opening (MMO) as primary and secondary outcomes, respectively. Risk of bias (RoB) was evaluated using the Cochrane tool, and evidence certainty was rated using the GRADE framework.</p><p><strong>Results: </strong>Ten RCTs met the inclusion criteria, with follow-up periods ranging from 30 minutes to 6 months. Six trials demonstrated significant pain reduction after opioid injections, while one reported no difference following morphine use. Another study found mepivacaine more effective than morphine or saline. Regarding MMO, one trial showed no effect of morphine, whereas two trials found that 1 mg morphine or 1 ml buprenorphine led to greater improvements than 0.1 mg morphine. In three trials, opioids enhanced MMO more than sodium hyaluronate. All studies exhibited low RoB. Certainty of evidence was moderate in six RCTs and low in three.</p><p><strong>Conclusion: </strong>There is no credible evidence for the benefit of intra-articular opioid-injections for managing TMJ nociception.</p><p><strong>Protocol registration: </strong>www.crd.tork.ac.uk/prospero identified is CRD42024598035.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"441-447"},"PeriodicalIF":1.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of conditioning + open-label placebo for post-operative pain management in adolescent idiopathic scoliosis.","authors":"Kira S Furie, Kaitlyn James, Ted J Kaptchuk, Mohammad Diab","doi":"10.1080/17581869.2025.2520148","DOIUrl":"10.1080/17581869.2025.2520148","url":null,"abstract":"<p><p>The vast majority of placebos are administered with concealment or deception. Most clinicians and researchers believe that either deception or concealment is necessary to achieve a placebo response; however, recent studies with open-label placebo (OLP), conditioning, and conditioning + OLP (COLP) have shown that placebos can be effective even when patients know they are receiving a placebo. To date, no studies have examined COLP in a pediatric surgical population, which is vulnerable to developing opioid dependence. COLP may assist in lowering opioid doses administered and quicker tapering off opioids. This study investigates the effectiveness of COLP on postoperative treatment of patients ages 10 through 17 undergoing posterior fusion for adolescent idiopathic scoliosis (AIS). It is a randomized controlled trial of 64 AIS patients assigned to one of the two arms: COLP + treatment as usual (TAU) and TAU control. Randomization and baseline assessments occur at the preoperative visit. Opioid consumption is recorded weekly after hospitalization until the first in-person postoperative visit at 6 weeks. The primary outcome measure is postoperative opioid consumption, both amount and duration. Secondary outcomes include pain, functional ability, and mental health scores.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"363-371"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative pain management after ureteroscopy: focused approaches to reducing opiate dependence.","authors":"Christopher C Ballantyne, Karen L Stern","doi":"10.1080/17581869.2025.2515001","DOIUrl":"10.1080/17581869.2025.2515001","url":null,"abstract":"<p><p>Ureteroscopy (URS) is a common urological procedure performed to treat nephrolithiasis, but postoperative pain often leads to patient inquires, unplanned emergency department visits, or readmissions. Effective pain management is essential for improving recovery, reducing adverse symptoms, and enhancing patient satisfaction. Due to concern for opioid dependency, urologists have increasingly focused on alternative methods for pain relief, emphasizing multimodal analgesia. This narrative review, based on a PubMED search from January 2025-February 2025, examines alternative strategies for pain management. Recent studies show benefits of combining medications like nonsteroidal anti-inflammatory (NSAIDS), alpha-blockers, and anticholinergics to reduce opioid dependence. Identifying the most appropriate analgesics following URS remains a challenge, with the primary goal to optimize recovery to improve patient outcomes and satisfaction.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"401-411"},"PeriodicalIF":1.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multimodal intervention of manual therapy, exercise, and psychological management for painful diabetic neuropathy: intervention development and feasibility trial protocol.","authors":"David Hohenschurz-Schmidt, Sasha Smith, Annina B Schmid, Philip Bright, Jerry Draper-Rodi, Matthew C Evans, Harriet Kemp, Nuno Koch Esteves, Elizabeth Pigott, Whitney Scott, Jan Vollert, Esther Williamson, Esther M Pogatzki-Zahn, Steven Vogel","doi":"10.1080/17581869.2025.2515010","DOIUrl":"10.1080/17581869.2025.2515010","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic options for people experiencing neuropathic pain from diabetic peripheral neuropathy are limited, and impact can be severe. Physical and psychological interventions remain under-explored but may offer promise, especially in multimodal combination programs.</p><p><strong>Objectives and methods: </strong>To address this gap, an intervention was developed according to the Medical Research Council's framework for complex interventions, including research expert and stakeholder input. This will be tested for acceptability and feasibility in a trial.</p><p><strong>Results: </strong>NeuOst (Neuropathy Optimisation through Self-management and Therapy) is a manual therapy-based intervention, incorporating exercise, psychologically informed training, and education. The protocol for a single-site, parallel, three-arm, partially participant-blinded, randomized controlled trial is presented. The experimental treatment is a 5-week course of NeuOst as adjunct to patients' usual care. Comparators are a control intervention that lacks pre-specified components of interest as adjunct to usual care and usual care only in adults with painful diabetic peripheral neuropathy. The follow-up period is 16 weeks. Primary outcomes are feasibility measures such as recruitment, eligibility, and consent rates, retention, blinding, fidelity, acceptability, and safety. Secondary and exploratory outcomes involve clinical measures and qualitative feedback. A protocol was prospectively registered (NCT06423391).</p><p><strong>Conclusion: </strong>After initial intervention development, a feasibility trial will inform intervention refinement and future research steps.</p><p><strong>Clinical trial registration: </strong>www.clinicaltrials.gov identifier is NCT06423391.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"387-399"},"PeriodicalIF":1.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}